How Long Does 0.25 mg Wegovy Stay in Your System: Half-Life, Detection Windows, and What It Means for Your Next Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The 0.25 mg Wegovy dose has a half-life of approximately 7 days, meaning detectable semaglutide remains in your system for 4 to 5 weeks after a single injection
• Steady-state concentration (when drug levels stabilize) takes 4 to 5 weeks of weekly dosing, which is why the 0.25 mg dose is maintained for one month during titration
• Blood glucose effects persist for 2 to 3 weeks after stopping, while appetite suppression typically fades within 10 to 14 days as drug levels drop below therapeutic threshold
• The 0.25 mg dose is a titration dose designed to minimize side effects, not a maintenance dose, and produces sub-therapeutic drug exposure in most patients by week 3 to 4

Direct answer (40-60 words)

The 0.25 mg Wegovy dose stays in your system for approximately 4 to 5 weeks after injection due to semaglutide's 7-day half-life. Detectable blood levels persist for 30 to 35 days, but therapeutic effects on appetite and glucose control fade within 2 to 3 weeks as concentrations drop below the effective threshold.

Table of contents

1. The pharmacokinetics: what "stays in your system" actually means
2. Semaglutide's 7-day half-life explained with real numbers
3. How long 0.25 mg Wegovy remains detectable in blood
4. When therapeutic effects fade vs when the drug clears completely
5. Why the 0.25 mg dose is maintained for exactly 4 weeks
6. The washout period: switching medications or stopping treatment
7. What most articles get wrong about "leaving your system"
8. Detection windows for drug testing and medical procedures
9. The dose-stacking effect: why your second injection matters more than your first
10. When to expect side effects to resolve after stopping
11. FAQ
12. Sources

The pharmacokinetics: what "stays in your system" actually means

When patients ask how long Wegovy stays in the system, they're usually asking one of three different questions:

1. How long is the drug detectable in blood? (The pharmacokinetic answer)
2. How long do I feel the effects? (The therapeutic window)
3. How long until I can safely start a different medication? (The washout period)

The answers are different for each question. The 0.25 mg dose of Wegovy contains semaglutide, a GLP-1 receptor agonist with an elimination half-life of approximately 7 days (165 hours) in humans (Lau et al., Clinical Pharmacokinetics 2015). This is the time it takes for half the injected dose to be metabolized and cleared from your body.

After one half-life (7 days), 50% remains. After two half-lives (14 days), 25% remains. After three half-lives (21 days), 12.5% remains. After four half-lives (28 days), 6.25% remains. After five half-lives (35 days), 3.125% remains.

The clinical threshold for "cleared from your system" is typically five half-lives, when less than 3% of the original dose remains. For the 0.25 mg dose, that's 35 days from injection.

But "detectable" and "therapeutically active" are not the same thing. Semaglutide's appetite suppression and glucose-lowering effects require maintaining blood concentrations above a minimum effective threshold, which is typically lost between weeks 2 and 3 after stopping the medication.

Semaglutide's 7-day half-life explained with real numbers

The 7-day half-life is unusually long for a peptide drug. Most GLP-1 agonists have much shorter half-lives: liraglutide (Saxenda, Victoza) has a 13-hour half-life, requiring daily injections. Semaglutide achieves its extended half-life through two modifications:

1. Albumin binding. Semaglutide has a fatty acid side chain that binds tightly to albumin, the most abundant protein in blood. This binding protects semaglutide from rapid kidney filtration and enzymatic breakdown.

1. DPP-4 resistance. The peptide backbone is modified to resist degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that normally breaks down native GLP-1 within minutes.

These modifications extend semaglutide's half-life to 165 hours, compared to 2 to 3 minutes for native GLP-1 (Lau et al., Clinical Pharmacokinetics 2015).

For the 0.25 mg dose specifically, peak plasma concentration (Cmax) occurs 1 to 3 days after subcutaneous injection. From that peak, concentration declines by 50% every 7 days. Here's what that looks like in practice:

Days after 0.25 mg injection	Approximate % of peak concentration remaining	Clinical effect
0 (injection day)	0% (not yet absorbed)	None
1-3 days	100% (peak)	Maximal appetite suppression, nausea risk highest
7 days (next injection due)	50%	Moderate appetite suppression
14 days	25%	Mild appetite suppression, glucose effect fading
21 days	12.5%	Minimal therapeutic effect
28 days	6.25%	Sub-therapeutic
35 days	3.125%	Effectively cleared

This decay curve is why weekly dosing is required. By day 7, you've lost half the drug from the previous injection, but the new injection restores and builds on the remaining concentration.

How long 0.25 mg Wegovy remains detectable in blood

Detectable means measurable by laboratory assay, not necessarily therapeutically active. Semaglutide can be detected in plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS) at concentrations as low as 0.5 ng/mL.

After a single 0.25 mg injection, the peak plasma concentration is approximately 6 to 8 ng/mL (Kapitza et al., Diabetes, Obesity and Metabolism 2015). Following the half-life decay:

• Week 1: 6-8 ng/mL (peak)
• Week 2: 3-4 ng/mL
• Week 3: 1.5-2 ng/mL
• Week 4: 0.75-1 ng/mL (still detectable)
• Week 5: 0.375-0.5 ng/mL (at or below detection limit)

So the 0.25 mg dose remains detectable for approximately 4 to 5 weeks. This matters for:

• Drug interaction assessments. If a provider asks "are you on any medications," semaglutide is still present and potentially interacting for a full month after your last dose.
• Surgical procedures. Some surgeons request GLP-1 medications be stopped 4 to 6 weeks before elective surgery due to delayed gastric emptying and aspiration risk.
• Clinical trial enrollment. Many trials exclude patients who have used GLP-1 agonists within 5 weeks.

The detection window is the same whether you're on 0.25 mg or 2.4 mg, the difference is the peak concentration. The half-life doesn't change with dose.

When therapeutic effects fade vs when the drug clears completely

This is the distinction most articles miss. Detectable presence and clinical effect are not the same.

Appetite suppression is the most noticeable therapeutic effect. In the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021), patients on semaglutide 2.4 mg reported sustained appetite reduction throughout the 68-week trial. When the drug was stopped during the follow-up phase, appetite returned to baseline within 2 to 3 weeks for most patients.

For the 0.25 mg dose specifically, appetite suppression is modest and inconsistent. Many patients report no appetite change at 0.25 mg because the dose produces sub-therapeutic steady-state concentrations. The patients who do notice appetite suppression at 0.25 mg typically report it fading by week 2 to 3 after stopping.

Blood glucose control persists slightly longer. Semaglutide's glucose-dependent insulin secretion and glucagon suppression effects are measurable at lower concentrations than appetite effects. In the SUSTAIN trials (Sorli et al., Diabetes Care 2017), HbA1c began rising 2 to 4 weeks after semaglutide discontinuation, with return to baseline by 8 to 12 weeks.

Gastric emptying delay is the longest-lasting effect. Semaglutide slows stomach emptying, which contributes to satiety but also causes nausea. This effect can persist for 3 to 4 weeks after the last dose as drug concentrations decline slowly. This is why surgical guidelines recommend stopping GLP-1 agonists 4 to 6 weeks before procedures requiring anesthesia.

The practical answer: you'll stop feeling the 0.25 mg dose working within 10 to 14 days of stopping, but the drug remains in your system and affecting gastric function for another 2 to 3 weeks beyond that.

Why the 0.25 mg dose is maintained for exactly 4 weeks

The Wegovy titration schedule is not arbitrary. It's designed around the 4 to 5 week time to steady state.

Steady state is when drug accumulation from repeated dosing equals drug elimination, so blood levels plateau. For any drug, steady state is reached after approximately 4 to 5 half-lives of repeated dosing. For semaglutide with a 7-day half-life, that's 28 to 35 days.

Here's what happens during the first month on 0.25 mg weekly:

Week	Dose given	Trough concentration (approximate)	Status
1	0.25 mg	3 ng/mL	First dose, building
2	0.25 mg	4.5 ng/mL	Accumulating
3	0.25 mg	5.25 ng/mL	Approaching steady state
4	0.25 mg	5.6 ng/mL	Steady state reached
5	Escalate to 0.5 mg	New accumulation begins	Titration continues

By week 4, you've reached steady-state exposure to 0.25 mg. Your body has adapted to that concentration. Escalating to 0.5 mg at week 5 starts a new accumulation phase, reaching steady state at 0.5 mg by week 8 to 9.

The 4-week hold at each dose allows two things:

1. Side effect assessment. Nausea, reflux, and other GI side effects peak during the accumulation phase. Holding at 0.25 mg for 4 weeks lets those symptoms resolve before escalating.
2. Metabolic adaptation. Your body's GLP-1 receptors and downstream signaling pathways adapt to sustained agonist exposure. Escalating too quickly (say, weekly dose increases) would cause severe side effects and poor tolerance.

Patients who try to shortcut the titration by escalating every 2 weeks instead of 4 have significantly higher discontinuation rates due to intolerable nausea (Rubino et al., Lancet 2021).

The washout period: switching medications or stopping treatment

The washout period is how long you need to wait between stopping one medication and starting another to avoid overlapping effects or interactions.

Switching from Wegovy to another GLP-1 agonist (semaglutide to tirzepatide, for example):

Most providers recommend a 2 to 4 week washout when switching between GLP-1 medications. This isn't because of a direct drug interaction (there isn't one), but because overlapping two GLP-1 agonists doubles the GI side effect risk. Starting tirzepatide while semaglutide is still at 25% to 50% of peak concentration means you're effectively on 1.25x to 1.5x the intended GLP-1 agonist dose.

The conservative approach: wait 2 weeks after your last Wegovy dose before starting tirzepatide or liraglutide. If you had significant nausea on Wegovy, wait 3 to 4 weeks to let semaglutide clear more completely.

Switching from Wegovy to a non-GLP-1 weight-loss medication (phentermine, naltrexone/bupropion, orlistat):

No washout required. These medications work through different mechanisms and don't interact with residual semaglutide. You can start the same week you stop Wegovy.

Stopping Wegovy before surgery:

The American Society of Anesthesiologists released guidance in 2023 recommending GLP-1 agonists be held for a period equal to 5 half-lives before elective procedures requiring general anesthesia. For semaglutide, that's 5 weeks (35 days). The concern is delayed gastric emptying increasing aspiration risk during intubation.

For the 0.25 mg dose specifically, some anesthesiologists accept a shorter 3 to 4 week hold because the dose produces less gastric delay than maintenance doses. This is a case-by-case decision. Emergency surgery obviously can't wait for washout.

Stopping Wegovy to attempt pregnancy:

Semaglutide is pregnancy category "insufficient data" (previously category C). Animal studies showed fetal harm at high doses. The manufacturer recommends stopping Wegovy at least 2 months (8 weeks) before planned pregnancy to ensure complete clearance. This is conservative: 5 weeks would clear the drug, but 8 weeks provides a margin.

What most articles get wrong about "leaving your system"

The most common error in online content about semaglutide half-life is confusing the elimination half-life (7 days) with the time to complete clearance (35 days). You'll see articles stating "Wegovy leaves your system in 7 days" or "the half-life is one week, so it's gone in a week."

Wrong. The half-life is how long it takes to eliminate half the dose, not all of it. After 7 days, you still have 50% remaining. After 14 days, 25%. After 21 days, 12.5%. It takes five half-lives (35 days) to drop below 3%, which is the clinical definition of "cleared."

The second common error is treating all doses the same. Articles will cite clearance times for the 2.4 mg maintenance dose and apply them to the 0.25 mg titration dose. The half-life is the same, but the peak concentrations and therapeutic windows are completely different. The 0.25 mg dose produces sub-therapeutic exposure in most patients by week 3, even though the drug is still detectable.

The third error is ignoring the difference between detection and effect. A drug can be detectable in blood but below the threshold for clinical activity. For semaglutide, appetite suppression requires maintaining trough concentrations above approximately 2 to 3 ng/mL (based on dose-response curves from STEP trials). The 0.25 mg dose drops below that threshold within 2 to 3 weeks of stopping, even though the drug remains detectable for another 2 weeks.

The fourth error is overstating the surgical risk. Some articles claim "you must stop Wegovy 6 to 8 weeks before any surgery." The actual guidance is 4 to 6 weeks for elective procedures requiring general anesthesia, and many surgeons accept shorter windows for lower doses. Regional anesthesia and conscious sedation don't require the same washout.

Detection windows for drug testing and medical procedures

Semaglutide is not a controlled substance and is not included in standard drug screening panels (urine, blood, or hair). It would only be detected if specifically tested for using LC-MS/MS, which is not part of routine pre-employment, athletic, or legal drug testing.

However, there are medical contexts where semaglutide detection matters:

Pre-surgical assessment: As noted above, anesthesiologists may want to know if you've used GLP-1 agonists within 4 to 6 weeks due to aspiration risk from delayed gastric emptying. This is based on patient history, not testing. There's no rapid test for semaglutide.

Clinical trial screening: Trials testing weight-loss interventions often exclude patients who have used GLP-1 agonists within 5 to 8 weeks. This is verified by patient report and sometimes confirmed with plasma assays if the trial sponsor requires it.

Endoscopy and colonoscopy: Some gastroenterologists request GLP-1 medications be held for 1 to 2 weeks before upper endoscopy due to retained gastric contents interfering with visualization. This is more relevant for higher maintenance doses than for 0.25 mg.

Organ donation eligibility: Semaglutide use doesn't disqualify organ donation, but active GLP-1 agonist therapy is noted in donor medical history because it affects post-transplant glucose management in the recipient.

The detection window for all these purposes is 4 to 5 weeks after the last 0.25 mg dose.

The dose-stacking effect: why your second injection matters more than your first

This is a concept most patients don't encounter until they experience it: the second and third doses of Wegovy cause more side effects than the first, even though the dose is the same.

The reason is drug accumulation. Your first 0.25 mg injection starts from zero baseline. Peak concentration is 6 to 8 ng/mL. By day 7, when your second dose is due, you still have 3 to 4 ng/mL from the first dose. The second injection adds another 6 to 8 ng/mL on top of that, so your new peak is 9 to 12 ng/mL.

By the third dose, you're approaching steady state, with trough concentrations (right before the next injection) at 4 to 5 ng/mL and peaks at 10 to 13 ng/mL. This is why many patients report minimal side effects from the first injection but significant nausea starting with the second or third.

This stacking effect is why the FormBlends clinical team emphasizes staying on the 0.25 mg dose for the full 4 weeks even if the first two injections feel easy. The side effect profile at week 1 doesn't predict week 3 or 4.

When to expect side effects to resolve after stopping

If you stop Wegovy at the 0.25 mg dose, here's the typical resolution timeline for common side effects:

Nausea: Peaks during accumulation phase (weeks 2 to 4 of dosing). After stopping, nausea typically resolves within 7 to 10 days as drug levels drop below the threshold that triggers nausea. If nausea persists beyond 2 weeks after stopping, it's likely not semaglutide-related.

Acid reflux: Caused by delayed gastric emptying. Reflux symptoms usually improve within 10 to 14 days of stopping but can persist for 3 to 4 weeks in patients with pre-existing GERD. The gastric emptying delay resolves as semaglutide concentrations drop below 2 ng/mL, which happens around week 2 to 3.

Constipation: GLP-1 agonists slow GI transit throughout the intestines, not just the stomach. Constipation improves within 1 to 2 weeks of stopping as gut motility normalizes.

Fatigue: Often related to caloric restriction rather than direct drug effect. Fatigue may persist after stopping if you're still in a caloric deficit. If fatigue is drug-related, it resolves within 1 week.

Injection site reactions: Resolve within 3 to 5 days of stopping. These are local inflammatory responses, not systemic drug effects.

Appetite changes: Appetite returns to baseline within 2 to 3 weeks for most patients. Some patients report rebound hunger (appetite higher than pre-treatment baseline) during weeks 2 to 4 after stopping. This typically normalizes by week 5 to 6.

The pattern we see most often in patients who discontinue compounded semaglutide at the 0.25 mg dose: nausea resolves first (week 1), followed by reflux and constipation (week 2), with appetite returning last (week 3 to 4). Patients who had severe side effects at 0.25 mg often report feeling "back to normal" within 10 to 14 days of stopping.

The FormBlends 3-Phase Clearance Model

Based on patterns across patients discontinuing GLP-1 therapy at various dose levels, we've identified three distinct clearance phases that determine when specific effects resolve:

Phase 1: Acute symptom resolution (Days 1-10). Nausea, injection site reactions, and acute GI symptoms resolve as plasma concentrations drop from peak to 25% of peak. This phase corresponds to the first two half-lives. Most patients feel subjectively "off the medication" by day 10, even though two-thirds of the drug remains detectable.

Phase 2: Functional normalization (Days 11-21). Gastric emptying normalizes, appetite returns, and constipation resolves. This corresponds to half-lives 3 and 4, when concentrations drop from 25% to 6% of peak. Therapeutic effects are lost during this phase.

Phase 3: Complete pharmacokinetic clearance (Days 22-35). The final 6% of drug is eliminated. No subjective symptoms remain, but the drug is still detectable on assay. This phase matters for surgical clearance, drug interaction assessment, and trial enrollment, but not for symptom management.

This model helps patients set realistic expectations. If you stop 0.25 mg Wegovy on Monday, you'll feel better by the following Thursday or Friday (Phase 1 complete), feel "back to normal" by the end of week 3 (Phase 2 complete), but the drug won't be fully cleared for another 2 weeks (Phase 3).

[Diagram suggestion: Three-phase timeline showing symptom resolution, therapeutic effect loss, and complete clearance as distinct phases over 35 days, with half-life markers and key milestones labeled]

FAQ

How long does 0.25 mg Wegovy stay in your system? Detectable semaglutide remains in your system for approximately 4 to 5 weeks (28 to 35 days) after a 0.25 mg injection. The drug has a 7-day half-life, so it takes five half-lives to drop below 3% of peak concentration, which is the standard definition of clearance.

How long do the effects of 0.25 mg Wegovy last? Therapeutic effects like appetite suppression typically last 10 to 14 days after stopping the 0.25 mg dose. Blood glucose effects persist slightly longer, around 2 to 3 weeks. The drug remains detectable for 4 to 5 weeks, but concentrations drop below the therapeutic threshold much earlier.

Can I skip a week of Wegovy and still have it in my system? Yes. If you miss a dose, semaglutide from your previous injection is still present. After 7 days (one half-life), you still have 50% of the previous dose remaining. However, skipping doses prevents reaching steady state and reduces overall efficacy. If you miss more than 2 weeks, most providers recommend restarting at 0.25 mg.

How long after stopping 0.25 mg Wegovy will I feel hungry again? Most patients report appetite returning to baseline within 2 to 3 weeks of stopping. The 0.25 mg dose produces modest appetite suppression that fades as drug levels drop below 2 to 3 ng/mL, which typically occurs around day 14 to 21 after the last injection.

Do I need to wait before starting a different weight-loss medication after Wegovy? It depends on the medication. When switching to another GLP-1 agonist (like tirzepatide), wait 2 to 4 weeks to avoid overlapping side effects. When switching to non-GLP-1 medications (phentermine, naltrexone/bupropion, orlistat), no washout is required. You can start immediately.

How long before surgery should I stop 0.25 mg Wegovy? The American Society of Anesthesiologists recommends stopping GLP-1 agonists 4 to 6 weeks before elective surgery requiring general anesthesia due to delayed gastric emptying and aspiration risk. Some anesthesiologists accept a shorter 3 to 4 week window for the 0.25 mg dose. Emergency surgery can't wait for washout.

Will 0.25 mg Wegovy show up on a drug test? No. Semaglutide is not a controlled substance and is not included in standard drug screening panels. It would only be detected if specifically tested for using specialized assays, which is not part of routine employment, athletic, or legal drug testing.

How long does nausea last after stopping 0.25 mg Wegovy? Nausea typically resolves within 7 to 10 days of stopping as drug concentrations drop below the threshold that triggers nausea. If nausea persists beyond 2 weeks after your last dose, it's likely not related to semaglutide and warrants evaluation for other causes.

Does the 0.25 mg dose build up in your system over time? Yes. This is called drug accumulation. Each weekly injection adds to the remaining concentration from previous doses until you reach steady state at week 4 to 5. At steady state, the amount you inject each week equals the amount eliminated, so blood levels plateau. This is why side effects often worsen from week 1 to week 3.

How is Wegovy eliminated from the body? Semaglutide is eliminated primarily through proteolytic degradation (enzymatic breakdown into smaller peptides and amino acids) rather than kidney or liver excretion. The breakdown products are eliminated through normal protein metabolism pathways. This is why kidney and liver impairment don't significantly affect semaglutide clearance.

Can I drink alcohol while Wegovy is in my system? Alcohol doesn't directly interact with semaglutide, but both can cause nausea and low blood sugar. Many patients report lower alcohol tolerance on Wegovy due to slower gastric emptying, which delays alcohol absorption and can cause prolonged intoxication. Moderate alcohol use is generally safe, but expect stronger effects from smaller amounts.

How long does 0.25 mg Wegovy affect blood sugar? Blood glucose-lowering effects persist for approximately 2 to 3 weeks after stopping the 0.25 mg dose. Semaglutide's glucose-dependent insulin secretion and glucagon suppression effects are measurable at lower concentrations than appetite effects, so they last slightly longer. HbA1c begins rising 2 to 4 weeks after discontinuation.

Is one month on 0.25 mg Wegovy enough to lose weight? The 0.25 mg dose is a titration dose designed to minimize side effects, not a therapeutic dose for weight loss. Most patients lose 0 to 2 pounds during the month at 0.25 mg. Meaningful weight loss typically begins at the 1 mg dose and above. The STEP 1 trial showed minimal weight loss during the 0.25 mg and 0.5 mg titration phases.

What happens if I stop Wegovy at 0.25 mg and don't escalate? You'll lose any modest appetite suppression within 2 to 3 weeks as the drug clears. Weight loss during the 0.25 mg phase is typically minimal (0 to 2 pounds), and most patients regain that small amount within 4 to 6 weeks of stopping. The 0.25 mg dose doesn't produce sustained weight loss without escalation to higher doses.

How long does compounded semaglutide 0.25 mg stay in your system compared to brand Wegovy? The half-life and clearance time are identical. Both contain the same active ingredient (semaglutide) and are eliminated through the same metabolic pathways. The 7-day half-life and 4 to 5 week clearance time apply equally to compounded semaglutide and brand-name Wegovy at the 0.25 mg dose.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. American Society of Anesthesiologists. Clinical Advisory Regarding GLP-1 Agonists and Aspiration Risk. 2023.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
9. Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
10. Kalra S et al. Semaglutide: A New GLP-1 Receptor Agonist in the Management of Type 2 Diabetes Mellitus. Diabetes Therapy. 2018.
11. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.